How effective is Teclistamab?

Teclistamab(Teclistamab) is a T cell-redirecting bispecific antibody that targets TCD3 expressed on the surface of T cells and B cell maturation antigen expressed on the surface of myeloma cells. In a phase 1-2 study, patients with relapsed or refractory myeloma who received at least three treatment regimens (including three types of immunomodulatory drugs, proteasome inhibitors and anti-CD38 antibodies) were recruited. Of the 165patients who received teritusumab, 77.6%had grade III refractory disease pan>(median, 5 prior lines of treatment). The median follow-up time was 14.1 months, and the overall response rate was 63.0%, with 65 patients (39.4%) achieving complete response or better. A total of 44patients(26.7%)were found to have no minimal residual disease(MR D) Among patients with complete response or better, the MRD-negative rate was 46%. The median duration of response was 18.4 months (95% confidence interval [CI], 14.9 to not estimable). The median duration of progression-free survival was 11.3 months (95% CI 8.8 to 17.1). Territuzumab resulted in high rates of deep and durable responses in patients with level III exposure of relapsed or refractory multiple myeloma. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to learn more about high-quality overseas drugs for you.